Evidence map›Paper›PMID 36653797›Full record

ArticleBMC complementary medicine and therapies2023

Beneficial effects of Panax notoginseng (Burkill) F. H. Chen flower saponins in rats with metabolic hypertension by inhibiting the activation of the renin-angiotensin-aldosterone system through complement 3.

Qiqi Huang, Jie Su, Jie Xu, Huanhuan Yu, Xiaohu Jin, Yajun Wang, Meiqiu Yan, Jingjing Yu, Suhong Chen, Youhua Wang and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Qiqi Huang *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jie Su *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jie XuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Huanhuan YuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Xiaohu JinSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Yajun WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Meiqiu YanSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jingjing YuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Suhong ChenCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, China. chensuhong@zjut.edu.cn.
Youhua WangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. doctorwyh@163.com.
Guiyuan LvSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China. zjtcmlgy@163.com.
Zhejiang Chinese Medical University · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNZhejiang University of Technology · CN

Funding

National Natural Science Foundation of China 81703772National Natural Science Foundation of China 81803819National Natural Science Foundation of China 81873036National Natural Science Foundation of China 82003977the Huadong MedicineJoint Funds of the Zhejiang Provincial Science Foundation of China LHDMZ22H280002the Key Laboratory of pharmacology research on hypertension and related diseases treated by traditional Chinese medicine in Zhejiang Province 2012E10002the Key Research and Development Program of Zhejiang Province 2020C04020
6 · The paper itself

Abstract

backgroundMetabolic hypertension (MH) has become the most common type of hypertension in recent years due to unhealthy eating habits and lifestyles of people, such as over-eating alcohol, high fat, and sugar diets (ACHFSDs). Therefore, effective means to combat MH are needed. Previous studies have shown that Panax notoginseng (Burkill) F. H. Chen flower saponins (PNFS) can lower blood pressure in spontaneously hypertensive rats (SHR). However, whether it acts on MH and its mechanism of action remain unclear. 

methodsThe pharmacodynamic effects of PNFS were evaluated in rats with ACHFSDs-induced MH. The blood pressure, blood biochemical, grip strength, face temperature, vertigo time, and liver index were estimated. The histological changes in the liver and aorta were observed using hematoxylin and eosin staining. The levels of ET-1, TXB

resultsIn the present study, PNFS was found to reduce blood pressure, face temperature, and vertigo time, increase grip strength and improve dyslipidemia in rats with MH. In addition, PNFS decreased the plasma levels of ET-1 and TXB

conclusionThe finding of the present study suggested that PNFS could downregulate C3 and KLF-5 expression in rats with MH, thereby inhibiting the overactivation of the renin-angiotensin-aldosterone system, while improving vascular endothelial function and ultimately reducing blood pressure in rats with MH.

Indexed as

HypertensionPanax notoginsengSaponinsAnimalsComplement C3FlowersRatsRats, Inbred SHRReninRenin-Angiotensin SystemVertigoComplement C3ReninSaponinsComplement 3Endothelial functionMetabolic hypertensionPanax notoginseng (Burkill) F. H. Chen flower saponinsRenin–angiotensin–aldosterone system

Identifiers

PMID36653797
PMCPMC9847118
OpenAlexW4317107734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.